On September 3, ASCENTAGE rose 5.02% in regular trading, trading at 34.14 HKD/share, with turnover of approximately 57.52 million HKD. The rally was driven by the World Chronic Lymphocytic Leukemia Day event catalyst, combined with CICC recently reaffirming its outperform rating on the company with a target price of 45 HKD.

On the fundamental side, Lisaftoclax (branded as Lishengto) has secured a Class I recommendation in the CSCO Lymphoma Diagnosis and Treatment Guidelines and has been included in 84 Huimin insurance programs across 194 cities in 27 provinces. The company is actively advancing national medical insurance negotiations. Additionally, the company reported H1 revenue of RMB 302 million, representing a 29.3% year-over-year increase, with product sales revenue growing 32.6%, reflecting continued strengthening of its commercialization capabilities. Multiple global registrational Phase III clinical trials, including GLORA, are underway around Lisaftoclax, accelerating the companys globalization progress. Separately, Guotai Junan Securities earlier initiated coverage with a buy rating and a target price of 59.09 HKD, citing robust commercial traction from both Olverembatinib and Lisaftoclax.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)